Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

BACKGROUND: Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased efficacy but are associated with specific side effects. The antibody‐drug conjugate depatuxizumab mafodotin (depatux‐m) targets EGFR with a mono...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969257/
https://ncbi.nlm.nih.gov/pubmed/29533458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31304
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge